Inactive Instrument

Mitsubishi Tanabe Pharma Corporation

4508

JP3469000008

Mitsubishi Tanabe Pharma Corporation(TSE:4508) dropped from S&P Global BMI Index

January 20, 2020 at 12:00 am EST

Latest news about Mitsubishi Tanabe Pharma Corporation

Grand Pharmaceutical Co., Ltd. entered into an equity acquisition agreement to acquire 75.35% stake in Tianjin Tanabe Seiyaku Co. Ltd. from Mitsubishi Tanabe Pharma Corporation for approximately HKD 400 million.	Dec. 20	CI
Certain Options of NewAmsterdam Pharma Company N.V. are subject to a Lock-Up Agreement Ending on 4-SEP-2023.	23-09-03	CI
Certain Warrants of NewAmsterdam Pharma Company N.V. are subject to a Lock-Up Agreement Ending on 4-SEP-2023.	23-09-03	CI
Certain Common Stock of NewAmsterdam Pharma Company N.V. are subject to a Lock-Up Agreement Ending on 4-SEP-2023.	23-09-03	CI
Mitsubishi Tanabe Pharma America Presents 48-Week Results from Global Phase 3 Safety Clinical Study of Radicava Ors®, an Oral Treatment for Als	22-06-01	CI
Mitsubishi Tanabe Pharma Corporation Announces Regulatory Approval of Dysval® (Valbenazine) for the Treatment of Tardive Dyskinesia in Japan	22-03-28	CI
Mitsubishi Tanabe Pharma America Presents REFINE-ALS Biomarker Study Details At Virtual 32nd International Symposium on ALS/MND	21-12-10	CI
Mitsubishi Tanabe Pharma Corporation Reports Earnings Results for the First Quarter Ended June 30, 2021	21-08-04	CI
Mitsubishi Tanabe Pharma America Announces EXSERVAN™ is Now Available in the U.S. for the Treatment of ALS	21-06-30	CI
Mitsubishi Tanabe Pharma Corporation Presents Data on Impact of ALS Symptoms on Patients' Ability to Independently Conduct Daily Activities	21-03-17	CI
Transcript : Mitsubishi Tanabe Pharma Corporation - Special Call	21-03-02
Pharma Foods International Co., Ltd. Enters into Exclusive Licensing Agreement with Mitsubishi Tanabe Pharma Corporation for A New Therapeutic Antibody to Treat Autoimmune Diseases	21-01-26	CI
Mitsubishi Tanabe Pharma Corporation Announces Board Changes	20-02-25	CI
Transcript : Mitsubishi Tanabe Pharma Corporation, Q3 2020 Earnings Call, Feb 04, 2020	20-02-04
Mitsubishi Tanabe Pharma Corporation Reports Consolidated Earnings Results for the Nine Months Ended December 31, 2019; Provides Earnings Guidance for the Year Ending March 31, 2020; Provides Dividend Guidance for the Year Ending March 31, 2020	20-02-04	CI
Nipro Pharma Corporation cancelled the acquisition of Tanabe Seiyaku Yoshiki Factory Co., Ltd. from Mitsubishi Tanabe Pharma Corporation.	20-01-30	CI
Mitsubishi Tanabe Pharma Corporation(TSE:4508) dropped from S&P Japan 500	20-01-20	CI
Mitsubishi Tanabe Pharma Corporation(TSE:4508) dropped from S&P Japan Mid Cap 100	20-01-20	CI
Mitsubishi Tanabe Pharma Corporation(TSE:4508) dropped from S&P Global BMI Index	20-01-20	CI
Mitsubishi Tanabe Pharma Corporation Announces Executive Changes, Effective April 1, 2020	20-01-14	CI
Mitsubishi Tanabe Pharma Corporation(TSE:4508) dropped from FTSE All-World Index	20-01-13	CI
Mitsubishi Chemical Holdings Corporation completed the acquisition of 35.18 % stake in Mitsubishi Tanabe Pharma Corporation.	20-01-06	CI
Mitsubishi Chemical : Chem to spend $4.5 billion to buy rest of Tanabe	19-11-18	RE
Mitsubishi Chemical Holdings Corporation made an offer to acquire remaining 43.61% stake in Mitsubishi Tanabe Pharma Corporation for approximately ¥490 billion.	19-11-17	CI
Biotech-for-hire PeptiDream charts new path and becomes short target	19-11-13	RE

Chart Mitsubishi Tanabe Pharma Corporation

Duration

Period

Chart Mitsubishi Tanabe Pharma Corporation

More charts

Mitsubishi Tanabe Pharma Corporation is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The medical supplies business is engaged in the research, development, manufacture and sale of ethical pharmaceutical and non-prescription drugs. The Company's subsidiaries receive raw materials from the company and sell products locally.

Sector

More about the company